established its strength in hematology and bacteriology for diagnostic purposes. By working closely with ST and combining its foundational microfluidic and other technology in the Molecular Mouse and our pathogen-specific assays, starting from a COVID-19 test, we’re ready to contribute to rapidly diagnosing, isolating, and ultimately stopping the spread of pathogens,” said Paolo Galiano, President of Alifax.
Alifax had been developing 4-5 assay panels for sepsis, and one assay to detect Zika, Dengue, Chikungunya when the pandemic began and pivoted to develop the Covid-19 assays. The sepsis and Zika, Dengue, and Chikungunya assays will follow soon.
Related Covid-19 test articles
- FIVE-MINUTE BREATH TEST UNDER DEVELOPMENT
- CONNECTED GRAPHENE SENSOR PERFORMS THREE TYPES OF TEST
- LAB-ON-A-CHIP STARTUP GETS BOOST
- PROTOTYPING PLATFORM FOR SILICON MICROFLUIDICS
Other articles on eeNews Europe